# Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

Article · Abraham Michael Lincoff, Stephen James Nicholls, Jeffrey Riesmeyer, Philip J. Barter, H Bryan Brewer, Keith A.A. Fox, Charles Michael Gibson, Christopher Bull Granger, Venu Menon, Gilles Montalescot, Daniel James Rader, Alan R. Tall, Ellen Strauss McErlean, Kathy Wolski, Giacomo Ruotolo, Burkhard Vangerow, Govinda J. Weerakkody, Shaun G. Goodman, Diego Conde, Darren K. McGuire, José Carlos Nicolau, Jose Luis Leiva-Pons, Yves Pesant, Weimin Li, David Kandath and 4 more

- Archive id: doi:10.1056/nejmoa1609581
- Published: 2017-05-17
- Venue: New England Journal of Medicine
- DOI: https://doi.org/10.1056/nejmoa1609581
- PMID: 28514624
- Citations: 801
- Source URL: https://doi.org/10.1056/nejmoa1609581
- PDF: https://www.nejm.org/doi/pdf/10.1056/NEJMoa1609581?articleTools=true
- Provenance: openalex

_Abstract not reproduced: its license does not permit redistribution. See the source URL._

Topics: [Cardiovascular Therapeutics](https://space-kitty.com/topics/cardiovascular-innovation)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.